Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy

Defects in nine sarcomeric protein genes are known to cause hypertrophic cardiomyopathy (HCM). Mutation types and frequencies in large cohorts of consecutive and unrelated patients have not yet been determined. We, therefore, screened HCM patients for mutations in six sarcomeric genes: myosin‐binding protein C3 (MYBPC3), MYH7, cardiac troponin T (TNNT2), α‐tropomyosin (TPM1), cardiac troponin I (TNNI3), and cardiac troponin C (TNNC1). HCM was diagnosed in 108 consecutive patients by echocardiography (septum >15 mm, septal/posterior wall >1.3 mm), angiography, or based on a state after myectomy. Single‐strand conformation polymorphism analysis was used for mutation screening, followed by DNA‐sequencing. A total of 34 different mutations were identified in 108 patients: 18 mutations in MYBPC3 in 20 patients [intervening sequence (intron) 7 + 1G > A and Q1233X were found twice], 13 missense mutations in MYH7 in 14 patients (R807H was found twice), and one amino acid change in TPM1, TNNT2, and TNNI3, respectively. No disease‐causing mutation was found in TNNC1. Cosegregation with the HCM phenotype could be demonstrated for 13 mutations (eight mutations in MYBPC3 and five mutations in MYH7). Twenty‐eight of the 37 mutation carriers (76%) reported a positive family history with at least one affected first‐grade relative; only eight mutations occurred sporadically (22%). MYBPC3 was the gene that most frequently caused HCM in our population. Systematic mutation screening in large samples of HCM patients leads to a genetic diagnosis in about 30% of unrelated index patients and in about 57% of patients with a positive family history.

[1]  M. Komajda,et al.  Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy , 2003, Circulation.

[2]  J. Seidman,et al.  Sarcomere Protein Gene Mutations in Hypertrophic Cardiomyopathy of the Elderly , 2002, Circulation.

[3]  E. Fleck,et al.  Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[4]  L. Leinwand,et al.  Low Sequence Variation in the Gene Encoding the Human β-Myosin Heavy Chain , 2001 .

[5]  A. Marian,et al.  The molecular genetic basis for hypertrophic cardiomyopathy. , 2001, Journal of molecular and cellular cardiology.

[6]  E. Wellnhofer,et al.  Novel mutation in the alpha-tropomyosin gene and transition from hypertrophic to hypocontractile dilated cardiomyopathy. , 2000, Circulation.

[7]  M. Gautel,et al.  A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. , 2000, Circulation.

[8]  J. Moolman-Smook,et al.  The origins of hypertrophic cardiomyopathy-causing mutations in two South African subpopulations: a unique profile of both independent and founder events. , 1999, American journal of human genetics.

[9]  M Hiroe,et al.  Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. , 1999, Biochemical and biophysical research communications.

[10]  A. Børglum,et al.  α-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy , 1999 .

[11]  H Niimura,et al.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.

[12]  M. Matsuzaki,et al.  Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy , 1997, Nature Genetics.

[13]  A. Marian,et al.  Prognostic significance of beta-myosin heavy chain mutations is reflective of their hypertrophic expressivity in patients with hypertrophic cardiomyopathy. , 1997, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[14]  T. Imaizumi,et al.  Clinical manifestations of hypertrophic cardiomyopathy with mutations in the cardiac beta-myosin heavy chain gene or cardiac troponin T gene. , 1996, Journal of cardiac failure.

[15]  F O Mueller,et al.  Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. , 1996, JAMA.

[16]  Y. Fujio,et al.  Clinical implications of hypertrophic cardiomyopathy associated with mutations in the alpha-tropomyosin gene. , 1996, Heart.

[17]  I. Rayment,et al.  Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle , 1996, Nature Genetics.

[18]  J. Beckmann,et al.  Cardiac myosin binding protein–C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy , 1995, Nature Genetics.

[19]  J. Seidman,et al.  Mutations in the cardiac myosin binding protein–C gene on chromosome 11 cause familial hypertrophic cardiomyopathy , 1995, Nature Genetics.

[20]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.

[21]  P. Brink,et al.  Clinical and prognostic evaluation of familial hypertrophic cardiomyopathy in two South African families with different cardiac beta myosin heavy chain gene mutations. , 1995, British heart journal.

[22]  Wigle Ed.  Novel insights into the clinical manifestations and treatment of hypertrophic cardiomyopathy. , 1995 .

[23]  I. Rayment,et al.  Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Christine E. Seidman,et al.  α-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere , 1994, Cell.

[25]  C. Hengstenberg,et al.  Familial hypertrophic cardiomyopathy. Microsatellite haplotyping and identification of a hot spot for mutations in the beta-myosin heavy chain gene. , 1993, The Journal of clinical investigation.

[26]  A. Chapelle,et al.  Disease gene mapping in isolated human populations: the example of Finland. , 1993, Journal of medical genetics.

[27]  J. Seidman,et al.  A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. Nihoyannopoulos,et al.  Identification of a mutation in the beta cardiac myosin heavy chain gene in a family with hypertrophic cardiomyopathy. , 1993, British heart journal.

[29]  J. Seidman,et al.  A molecular basis for familial hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutation , 1990, Cell.

[30]  L. Melton,et al.  Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. , 1989, Circulation.

[31]  T. Sekiya,et al.  Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[32]  B. Maron,et al.  Results of screening a large group of intercollegiate competitive athletes for cardiovascular disease. , 1987, Journal of the American College of Cardiology.

[33]  G. Lathrop,et al.  Easy calculations of lod scores and genetic risks on small computers. , 1984, American journal of human genetics.

[34]  L. Leinwand,et al.  Low sequence variation in the gene encoding the human beta-myosin heavy chain. , 2001, Genomics.

[35]  H. S. Kim,et al.  Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice. , 1999, The Journal of clinical investigation.

[36]  A. Børglum,et al.  Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. , 1999, The Journal of clinical investigation.

[37]  C R Scriver,et al.  Proof of “disease causing” mutation , 1998, Human mutation.

[38]  E. Wigle.  Novel insights into the clinical manifestations and treatment of hypertrophic cardiomyopathy. , 1995, Current opinion in cardiology.